Brief: Neurosense Expands Its Phase 2B ALS Trial To Canada And Withdraws Protocol From U.S. IND

Neurosense Therapeutics

06/02/2023 16:11

Feb 6 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE EXPANDS ITS PHASE 2B ALS PARADIGM TRIAL TO
CANADA AND
WITHDRAWS PROTOCOL FROM U.S. IND TO ALIGN ITS CLINICAL STRATEGY
WITH THE FDA FOR A POTENTIAL PIVOTAL PHASE 3 STUDY
    * NEUROSENSE THERAPEUTICS LTD - PARADIGM TOPLINE READ-OUT
EXPECTED
H2 2023
    * NEUROSENSE THERAPEUTICS LTD - PLANNING A FORMAL MEETING
WITH FDA
TO ALIGN ITS CLINICAL AND REGULATORY STRATEGY FOR A POTENTIAL
PIVOTAL PHASE 3 TRIAL

Source text for Eikon:  ID:nPn6jjBpza 
Further company coverage:  NRSN.O 
 ((Reuters.Briefs@thomsonreuters.com;))